20 articles
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
When the DNA-repair gene EXO1 is overproduced, it damages DNA instead of fixing it—exposing a hidden vulnerability in multiple cancers.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
New biotech innovations are advancing prostate cancer therapy with promising approaches for better patient outcomes.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
Researchers identify N4BP2, the enzyme behind chromothripsis - a genetic catastrophe that helps one in four cancers rapidly evolve and resist treatment.
Northwestern researchers dramatically boosted cancer vaccine effectiveness by simply repositioning one protein fragment on their nanovaccine.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
New research reveals why BET inhibitor cancer drugs work in labs but fail in patients, pointing to better treatment strategies.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months — reshaping treatment strategy.
